Literature DB >> 17379103

Erythropoietin and iron-restricted erythropoiesis.

Lawrence Tim Goodnough1.   

Abstract

Twenty five years ago, Finch summarized knowledge gained primarily from studies of normal individuals, patients with hereditary hemolytic anemias, and patients with hemochromatosis [1]. Under conditions of basal erythropoiesis in normal subjects, plasma iron turnover (as an index of marrow erythropoietic response) is little affected, whether transferrin saturation ranges from very low to very high levels. In contrast, the erythropoietic response in individuals with congenital hemolytic anemia, in whom erythropoiesis is chronically raised up to sixfold over basal levels [2], is affected (and limited) by serum iron levels and by transferrin saturation [3]. Patients with hemochromatosis who underwent serial phlebotomy were observed to mount erythropoietic responses of up to eightfold over basal rates, attributed to the maintenance of very high serum iron and transferrin saturation levels in these patients [4], whereas normal individuals were shown to have difficulty providing sufficient iron to support rates of erythropoiesis greater than three times basal rates [5]. These observations led Finch to identify a "relative iron deficiency" state, also known as "functional iron deficiency," which he defined as circumstances in which increased erythron iron requirements exceed the available supply of iron [6]. In another clinical setting, patients undergoing autologous blood donation represent a model for perisurgical blood loss and the erythropoietic response. Insights gained over the last 20 years regarding the relationship between erythropoietin, iron, and erythropoiesis, along with implications for clinical management, will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379103     DOI: 10.1016/j.exphem.2007.01.026

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.

Authors:  David P Steensma; Jeff A Sloan; Shaker R Dakhil; Robert Dalton; Stephen P Kahanic; Diane J Prager; Philip J Stella; Kendrith M Rowland; Paul J Novotny; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

Review 2.  Heme-regulated eIF2α kinase in erythropoiesis and hemoglobinopathies.

Authors:  Jane-Jane Chen; Shuping Zhang
Journal:  Blood       Date:  2019-11-14       Impact factor: 22.113

3.  The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Luciana Tanca; Maria Cristina Cherchi; Carlo Floris; Itaru Omoto; Antonio Barracca; Tomas Ganz
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

4.  Hepcidin and GDF15 in anemia of multiple myeloma.

Authors:  Shuchong Mei; Huaquan Wang; Rong Fu; Wen Qu; Limin Xing; Guojin Wang; Jia Song; Hong Liu; Lijuan Li; Xiaoming Wang; Yuhong Wu; Jin Guan; Erbao Ruan; Zonghong Shao
Journal:  Int J Hematol       Date:  2014-07-23       Impact factor: 2.490

5.  HRI coordinates translation by eIF2αP and mTORC1 to mitigate ineffective erythropoiesis in mice during iron deficiency.

Authors:  Shuping Zhang; Alejandra Macias-Garcia; Jason Velazquez; Elena Paltrinieri; Randal J Kaufman; Jane-Jane Chen
Journal:  Blood       Date:  2017-11-03       Impact factor: 22.113

Review 6.  Managing Genetic Hemochromatosis: An Overview of Dietary Measures, Which May Reduce Intestinal Iron Absorption in Persons With Iron Overload.

Authors:  Nils Thorm Milman
Journal:  Gastroenterology Res       Date:  2021-04-21

Review 7.  Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia.

Authors:  Wesley S Bond; Tonia S Rex
Journal:  Front Immunol       Date:  2014-10-22       Impact factor: 7.561

Review 8.  Iron deficiency in gastrointestinal oncology.

Authors:  Kristof Verraes; Hans Prenen
Journal:  Ann Gastroenterol       Date:  2015 Jan-Mar

9.  Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Authors:  Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

10.  The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study.

Authors:  Laurens Verhaeghe; Luk Bruyneel; Elisabeth Stragier; Marc Ferrante; Daan Dierickx; Hans Prenen
Journal:  Ann Gastroenterol       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.